Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors

MT Newswires Live11-21

Perspective Therapeutics (CATX) said Thursday that it will proceed with a dose escalation study of its radiopharmaceutical therapy candidate for the treatment of neuroendocrine tumors under an ongoing phase 1/2a trial after a consultation with the US Food and Drug Administration.

The company said the trial has tested two doses of the radiopharmaceutical therapy in nine patients, eight of whom showed "durable control of disease" and six had measurable reduction of tumor volume.

Perspective said no dose limiting toxicities were observed in the patients and the safety monitoring committee said safety observations support proceeding with the dose escalation and expanding patient enrollment.

Perspective Therapeutics Chief Medical Officer Markus Puhlmann said the company expects to "engage with the FDA in the coming weeks to pursue dose escalation."

Perspective Therapeutics shares were down 46% in recent trading.

Price: 3.25, Change: -2.93, Percent Change: -47.41

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment